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Abstract: Relationship between high-sensitivity C-reactive protein (hs-CRP) and adiposity 
by diabetes status and gender in Cuban-Americans with and without type 2 diabetes (T2D) 
was studied. Adult subjects, 226 females, 129 males participated in a case control, single 
time point study. Subjects with T2D were older, had higher waist circumference (WC) and 
body mass index (BMI). WC and BMI were associated with ln hs-CRP (P < 0.001). An 
interaction with diabetes status was found for BMI (P = 0.037). Gender showed a strong 
relationship with ln hs-CRP (P < 0.001), which was moderated by diabetes status.  Only 
males without diabetes exhibited a significant relationship for both WC and BMI with ln 
hs-CRP.  In this sample of Cuban-Americans, WC and BMI had stronger associations with 
ln hs-CRP but not with diabetes status. Obesity prevention and controlling for CRP levels 
may be necessary to eliminate its contributions to develop diabetes and cardiovascular 
disease (CVD). 
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1. Introduction  
As of 2007, approximately 24 million people in the United States had diabetes, with type 2 diabetes 
(T2D) accounting for 90–95% of all diabetes cases [1]. The incidence of diabetes is quickly 
multiplying, with an average of 1.6 million new cases diagnosed each year [2]. The most significant 
clinical consequence of T2D is mortality and morbidity from cardiovascular diseases (CVD), 
particularly coronary heart disease (CHD) and stroke [3]. Adults with diabetes are 2 to 4 times more 
likely to die from CHD and stroke than without diabetes, as almost 70% of deaths among those with 
diabetes are due to CHD or stroke [4,5]. 
Certain minority groups are at greater risk of diabetes than their Caucasian counterparts [6]. 
Specifically, Cuban-Americans between the ages of 45 and 74 have a 1.3 times higher prevalence of 
diabetes than similarly aged non-Hispanic whites according to the Hispanic Health and Nutrition 
Examination Survey (HHANES), a cross-sectional survey of the three major U.S. Hispanic populations 
conducted between 1982 and 1984 [7]. While HHANES provides data on the prevalence of diabetes 
for Cuban-Americans, it does not identify the risk factors and diabetes-related complications specific 
to this population. Furthermore, no data is available on the CHD risks in Cuban-Americans with T2D. 
Given that the prevalence of diabetes is about 16% among adult Cubans in the United States, it is of 
extreme importance that risk factors for CHD be identified in this rapidly proliferating, high-risk 
minority group [7].  
In the past decade, it has become widely accepted that inflammation plays a key role in the 
pathogenesis of CVD. C-reactive protein (CRP), an acute phase protein and marker of chronic,   
low-grade inflammation, is a reliable predictor of CVD [8]. Data from prospective, epidemiologic 
studies revealed a significant association between CRP and future CHD risk in apparently healthy 
subjects [9]. Similarly, high plasma CRP has been shown to be an independent risk factor for CHD 
deaths in T2D [10].  
CRP is made by the liver in response to inflammatory cytokines such as interleukin-6 (IL-6) and 
tumor necrosis factor-α (TNFα) [11]. Adipose tissue is a major source of these inflammatory   
cytokines [12]. Consequently, a strong positive association has been found between measures of 
obesity, such as waist circumference (WC) and body mass index (BMI), with CRP [13,14]. Moreover, 
while some studies have observed a relationship between T2D and higher CRP levels, it is unclear 
whether that relationship remains after adjustment for adiposity [15].  
In addition to body fatness, CRP can be affected by age, smoking, medications, biochemical 
indices, dietary factors, lifestyle factors, genetics and race. Previous studies have shown that certain 
medications have an effect on CRP levels in the body [16-22]. Oral hypoglycemic medications such as 
metformin and rosiglitazone, singly or as combined treatment resulted in lower CRP levels in subjects 
with T2D [16,17]. Similarly antihypertensive medications such as beta blockers decreased overall CRP 
levels. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) 
lowered CRP only in subjects on monotherapy [18]. Selective serotonin reuptake inhibitor
 (SSRI) 
therapy in subjects with depressive disorder significantly decreased CRP levels whether or not the 
depressive condition was resolved [19]. Usage of aspirin and azithromycin by adults with unstable 
angina and cystic fibrosis respectively lowered CRP levels and improved quality of life [20,21]. 
Hormone replacement therapy (HRT) and raloxifene on the other hand had no effect on CRP levels in Int. J. Environ. Res. Public Health 2010, 7          
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post menopausal women [22].  Dehghan  et al. found significantly different serum CRP levels 
depending on CRP haplotypes, which remained after adjustment for obesity measures [23]. 
Furthermore, the distribution of CRP and the relationship between CRP and obesity vary according to 
race and gender, with certain minority groups having greater risks associated with CRP [24-26]. Still, 
few data regarding CRP, obesity and CVD risk have been generated for minority populations, and no 
information is available for CRP and related variables for Cuban-Americans, either healthy or 
dysmetabolic. Therefore, the purpose of this study was: (a) to examine differences in high-sensitivity 
C-reactive protein (hs-CRP) levels and body fatness by diabetes status, and; (b) to determine whether 
the relationship of hs-CRP with adiposity varies by diabetes status and gender in Cuban Americans. 
 
2. Materials and Methods 
 
2.1. Subjects 
 
Data from a complete sample set of case control, single time point study of Cuban-Americans with 
and without T2D was used in the present study. Recruitment of participants was conducted in 
alternative phases of potential subjects with and without T2D. During a 1-year period, approximately 
10,000 letters outlining the study were mailed to subjects with and without diabetes ages 30 years or 
older. Letters were sent in English and Spanish, and included an invitation flyer to which interested 
participants could respond. The participants were initially recruited by random selection (every tenth 
address) from a randomly generated mailing list. The list of addresses was purchased from Knowledge 
Base Marketing Inc., Richardson, TX 75081. This company provided mailing list of Cuban Americans 
from Miami-Dade and Broward Counties, Florida. Three percent (n = 300) of the letters were returned 
due to unknown addresses. From the remaining delivered mail, 4% (n = 388) responded. Interested 
participants were initially interviewed on the phone, at which time the study purpose was explained 
and age and gender of the responders were determined. To ascertain T2D status, each participant was 
asked for the age of diagnosis and initial treatment modalities. Inclusion criteria for the T2D group 
were as follows: (1) Cuban-American, (2) self-reported T2D, (3) aged >30 years, male or female,  
(4) not pregnant or lactating, (5) no thyroid disorders, and (6) no major psychiatric disorders. Inclusion 
criteria for group without diabetes met the same criteria as subjects with T2D except they were free 
from any type of diabetes. Eighteen subjects did not qualify for the study; for not being   
Cuban-American (n = 2), age (n = 9) or having other chronic illness (n = 7). If a subject was 
determined to be eligible, then their participation was requested at the Human Nutrition Laboratory at 
Florida International University (FIU). Participants were instructed to refrain from smoking, 
consuming any food or beverages except water, and any unusual exercise for at least eight hours prior 
to their blood collection. The approved Institutional Review Board informed consent was presented to 
eligible participants in Spanish or English based on their preference and signatures were obtained prior 
to the commencement of the study. Three subjects were excluded due to missing values needed for 
analysis. We classified T2D based on the self-report of the participants and we were able to verify 
subjects’ own account by blood tests. Those who reported not having T2D (n = 7) were classified as 
having T2D based on fasting plasma glucose (FPG) and HbA1c analysis. Individuals were classified as 
having T2D based on the same criteria that was applied to those reported having T2D and those who Int. J. Environ. Res. Public Health 2010, 7          
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did not. HbA1c is an overtime measure of blood glucose. In individuals who reported not having T2D 
measuring HbA1c was a good indicator of FPG having been high at least 2−3 months prior to this 
measure. These subjects were given their laboratory results and referred to their physicians. 
 
2.2. Procedure 
  
Subjects were asked to fill out standard questionnaires on site. Trained interviewers who were 
bilingual in English and Spanish were present to administer the questionnaires. Through administration 
of questionnaires, information was obtained on subjects’ socio-demographic data, smoking history and 
status, diabetes status, diabetes care (for T2D only), anthropometric measurements and nutritional 
variables. Height and weight were measured using a SECA balance scale (Seca Corp, Columbia, MD). 
BMI was calculated as weight in kg/height in m
2. Waist circumference (WC) to the nearest 0.1 cm was 
measured horizontally with a non-stretchable measuring tape placed midway between the 12
th rib and 
iliac crest at minimal respiration to determine central obesity [27]. A 20 ml venous blood was collected 
from each subject after an overnight fast (at least 8 hours) by a certified phlebotomist using standard 
laboratory techniques. Blood samples were collected into 2 tubes: one containing K2EDTA to analyze 
HbA1c and the second a vaccutainer Serum Separator Tube (SST) for analysis of glucose. After 
complete coagulation (30–45 minutes), the SST was centrifuged at 2,500 RPM for 30 minutes. The 
serum was transferred from the spun SST into 3 labeled plastic tubes: the first tube was used for 
glucose analysis, and the second tube was stored at −70 °C to be used later for hs-CRP. Glucose levels 
were measured by hexokinase enzymatic methods by Laboratory Corporation of America, Miami, FL 
(LabCorp®). Hs-CRP was analyzed at the Vascular Disease Intervention and Research Laboratory, 
Edmond, OK using Immulite method. The Immulite assay is a 2-site chemiluminescent enzyme 
immunometric assay with one monoclonal and one polyclonal anti-CRP antibody. A 1:100 manual 
dilution of the antibody provides a measurable range of 0.1–500 mg/L [28].  
 
2.3. Statistical Analysis 
 
SPSS program (Version 15.0, Chicago, IL) was used for statistical analysis and statistical 
significance was accepted at P < 0.05. Data not normally distributed were natural log (ln) transformed 
to approach normality and outliers were excluded from analysis. Descriptive statistics were generated 
for all variables. Differences in mean values between subjects with and without T2D were assessed 
using the unpaired Student’s t-test for numerical values and chi-square test for categorical variables to 
test the first aim. Pearson’s correlations and Multiple Linear Regression (MLR) was conducted to test 
the second aim, using ln hs-CRP as a dependent variable and WC or BMI as independent variables 
stratified by gender and diabetes status. Age, smoking, non-steroidal anti-inflammatory drugs 
(NSAIDS), cholesterol medications, hypertension medications, depression medications and diabetes 
medications were included as controlling variables. 
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3. Results 
 
The present study analyzed 355 subjects, 226 females and 129 males. Characteristics of the study 
population are shown (Table 1). Subjects with T2D were older than subjects without diabetes   
(65.3 ± 12.1y vs. 62.5 ± 11.4y, respectively). Also, subjects with diabetes had significantly higher body 
adiposity with a greater BMI (31.6 ± 6.6 kg/m
2 vs. 30.1 ± 5.2 kg/m
2) and WC (105.7 ± 14.7 cm vs. 
100.3 ± 12.4 cm) than subjects without diabetes. Non-steroidal anti-inflammatory drug (NSAID) use 
was significantly higher in subjects without diabetes (50% vs. 31%, respectively). Subjects with T2D 
had significantly higher fasting plasma glucose (FPG) and HbA1c than those without (146.1 ± 65.7 vs. 
98.0 ± 17.9 and 7.5 ± 1.5 vs. 5.9 ± 0.6, respectively). Hs-CRP levels were skewed; therefore, values 
were natural log (ln) transformed. Ln hs-CRP was not significantly different for subjects with T2D 
than without diabetes. Similarly, no difference was detected between the two groups for gender, active 
smoking, cholesterol medication use, hypertension medication use or depression medication use.  
Table 1. Characteristics of study population by diabetic status. 
  
Variables 
Without Diabetes  With Diabetes   
P-value
†  (n = 178)  (n = 177) 
Age (years)  62.5 ± 11.4  65.3 ± 12.1  0.023 
Gender (female %)  65  60  0.322 
BMI (kg/m
2)  30.1 ± 5.2  31.6 ± 6.6  0.022 
WC (cm)  100.3 ± 12.4  105.7 ± 14.7  0.001 
Ln hs-CRP (mg/L)  1.03 ± 1.18  1.04 ± 1.23  0.901 
Active smokers (%) 18  15  0.667 
NSAID (yes %)  50  31  0.001 
Cholesterol meds (yes %)  18  21  0.510 
Hypertension meds (yes %)  47  53  0.289 
Depression meds (yes %)     14    11  0.516 
Diabetes meds (yes %)  
FPG (mg/dl)   
HbA1c (%) 
0 
98.0 ± 17.9 
        5.9 ± 0.6 
82.5 
146.1 ± 65.7 
 7.5 ± 1.5  
0.001 
0.001 
0.001 
Quantitative variables are expressed as mean ± standard deviation (SD). 
†Evaluated by t-test for 
numerical variables and chi-square test for categorical variables; P < 0.05 considered significant. 
Abbreviations: BMI, body mass index; WC, waist circumference; NSAID, non-steroidal anti-
inflammatory drug; meds, medications, FPG, fasting plasma glucose, HbA1c, glycated hemoglobin. 
FPG (n = 173 without diabetes and n = 174 with diabetes), HbA1c (n = 177 without diabetes and  
n = 174 with diabetes). 
 
After adjustment for age, smoking, diabetes status and medication use (NSAID, cholesterol, 
hypertension and depression medications), MLR revealed that WC, BMI, and gender were all 
significantly associated with ln hs-CRP (P < 0.05) (Tables 2 and 3).  
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Table 2. Relationship of waist circumference and covariates with ln hs-CRP layered by 
diabetes status. 
Parameter† B SE T  P-value‡ 
WC 0.043  0.007  6.183    <0.001 
Diabetes_Status*WC  −0.017 0.009 −1.850 0.065 
Gender  −0.333 0.129 −2.589 0.010 
† Other covariates appearing in the Multiple Linear Regression (MLR) are age, smoking, NSAID, 
cholesterol medication, hypertension medication, depression medication; diabetes medication.   
‡
 P < 0.05 is considered significant. Abbreviations: WC, waist circumference; SE, standard error; 
B, slope parameter; Diabetes_Status*WC, variable testing for interaction between diabetes status 
and waist circumference; Diabetes_Status = 1 with diabetes; 0 = without diabetes; Gender = 1 
male, 0 = female.  
 
Both WC and BMI showed a strong positive relationship with ln hs-CRP (P  < 0.001). No 
significant interaction was revealed for WC with diabetes status (P = 0.065) but an interaction between 
BMI and diabetes status was found (P < 0.05). The slope for the relationship between BMI and ln  
hs-CRP was stronger for persons without diabetes than with diabetes (B = 0.099 and B = 0.055, 
respectively), but both slopes were significantly different than zero (P < 0.001).  
Table 3. Relationship of body mass index and covariates with ln hs-CRP by diabetes status. 
Parameter† B  SE  T  P-value‡ 
BMI        
     Without Diabetes    0.099  656  −1.95   <0.001 
     With Diabetes  0.055  0.013  4.09   <0.001 
Diabetes_Status *BMI  −0.044 0.021 −2.089     0.037 
† Other covariates appearing in the Multiple Linear Regression (MLR) are age, gender, smoking, 
NSAID, cholesterol medication, hypertension medication, depression medication; diabetes 
medication. ‡
 P  < 0.05 is considered significant. Abbreviations: BMI, body mass index; SE, 
standard error; B, slope parameter; Diabetes_Status*BMI, variable testing for interaction between 
diabetes status and body mass index. 
 
Since gender was shown to be related to ln hs-CRP, further analysis was layered by gender and 
diabetes status (Table 4). No difference was found between males with diabetes and without diabetes 
for age, BMI, WC and ln hs-CRP. Females, however, varied significantly for age, BMI and WC. 
Specifically, females with diabetes were older and had greater BMIs and WCs than without diabetes  
(P < 0.05 for all variables).  
Pearson’s correlations showed that ln hs-CRP was significantly correlated with WC (r = 0.470,  
p = 0.001 and r = 0.406, p = 0.001) and BMI (r = 0.387, p = 0.001 and r = 0.395, p = 0.001) among 
females with and without diabetes. However, ln hs-CRP was significantly correlated with WC   
(r = 0.563, p = 0.001) and BMI (r = 0.548, p = 0.001) only among males without diabetes. MLR 
analysis showed that diabetes status did not affect the relationship between WC and BMI with ln  
hs-CRP in females. A significant difference moderated by diabetes status was found in males Int. J. Environ. Res. Public Health 2010, 7          
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associated with both WC (P = 0.004) and BMI (P = 0.009) with ln hs-CRP (Table 5). When controlling 
for age, smoking, and medications, males without diabetes exhibited a stronger and significant 
relationship between WC and ln hs-CRP compared with males with diabetes (B = 0.048, P < 0.001 and 
B = 0.004, P = 0.712, respectively). A similar association was revealed for BMI and ln hs-CRP, with 
males without diabetes showing a stronger relationship (B = 0.127, P < 0.001) than with diabetes  
(B = 0.020, P = 0.458). 
Table 4. Characteristics of subjects grouped by gender and diabetes status. 
  Males  
P-value†  Parameter Without  diabetes 
(n = 60) 
With Diabetes 
(n = 69) 
Age (years)  62.6 ± 11.4  63.8 ± 11.3  0.551 
BMI (kg/m
2)  29.4 ± 5.1  30.3 ± 5.3  0.325 
WC (cm)  102.9 ± 13.3  106.6 ± 13.7  0.123 
Ln hs-CRP  0.81 ± 1.18  0.95 ± 1.21  0.518 
     
  Females   
P-value†  Parameter Without  diabetes 
(n = 118) 
With Diabetes 
(n = 108) 
Age (years)  65.6 ± 11.3  66.11 ± 12.4  0.016 
BMI (kg/m
2)  30.5 ± 5.2  32.4 ± 7.1  0.024 
WC (cm)  98.9 ± 11.8  105.1 ± 15.3  0.001 
Ln hs-CRP  1.1 ± 1.2  1.1 ± 1.3  0.838 
Values are expressed as mean ± standard deviation (SD). †
 Evaluated by t-test; P < 0.05 considered 
significant. Abbreviations: BMI, body mass index; WC, waist circumference. 
Table 5. Relationship of waist circumference and BMI with ln hs-CRP by diabetes status 
for male subjects. 
Diabetes 
Status 
Waist Circumference   
 B  SE  t  P-value† 
Without   
 diabetes 
0.048 0.011 4.41   <0.001 
With Diabetes  0.004  0.010  0.37  0.712 
        
  BMI   
 B  SE  t  P-value† 
Without 
diabetes 
0.127 0.029 4.35   <0.001 
With Diabetes  0.020  0.027  0.74  0.458 
Other covariates appearing in the Multiple Linear Regression (MLR) are age, smoking, NSAID, 
cholesterol medication, hypertension medication, depression medication; diabetes medication.   
† P < 0.05 is considered significant. Abbreviations: SE, standard error; BMI, body mass index; B, 
slope parameter. Int. J. Environ. Res. Public Health 2010, 7          
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4. Discussion 
 
The present study confirms previous observations regarding the systemic inflammation associated 
with greater adiposity as measured by waist circumference and BMI [13,14,24,26,29]. Hs-CRP did not 
vary by to diabetes status, but was strongly associated with both waist circumference and BMI. These 
results are congruent with findings from other investigations [15,24]. Efstratiadis et al. discovered that 
after controlling for BMI and various CRP confounders, diabetes was not associated with CRP [30]. 
Still, prospective, epidemiological studies have shown high CRP to be a major contributor to the risk 
of T2D, independent of measures of body adiposity [23].  
Data from HHANES revealed that among Cuban American individuals 18 years or older the 
prevalence of obesity was 15% for females and 9% for males [31]. The National Health Interview 
Survey, Sample Adult File (NHIS-SAF) and HHANES indicated that the prevalence of obesity and 
diabetes varies among Hispanics [32]. Mexican Americans had a higher prevalence of obesity (25.3%) 
and diabetes (23.9%) compared to Cuban Americans (20.2% and 15.8% respectively) [7,32]. In 
contrast, according to the National Vital Statistics System (NCHS) diabetes related deaths was higher 
among Cuban Americans (44%) compared Puerto Ricans (39%) and Mexican Americans (37%) [33].  
Subjects with diabetes were found to be older and more obese than subjects without diabetes in this 
group of Cuban-Americans, which is in agreement with results from multi-ethnic   
populations [30,34,35]. However, it is important to consider the influence of race and ethnicity when 
interpreting the results of the present study. Patel et al. examined the relation of CRP with waist 
circumference and other correlates of the metabolic syndrome [25]. Racial differences were found for 
the association of waist circumference and CRP, highlighting the need for a better understanding of the 
significance of CRP and clinical relevance of values for various ethnicities and races. Indeed, the 
majority of the current literature on CRP has been generated from mostly Caucasian populations. To 
our knowledge, this study was the first to investigate the relationship of obesity and diabetes with hs-
CRP in a Cuban-American population. Thus, the present analysis is largely exploratory in nature, but 
serves to add clinical insight on the inflammatory burden of non-white populations.  
Our investigation also revealed the possibility of a gender influence on hs-CRP and body fatness. 
Females exhibited a strong association for both waist circumference and BMI with hs-CRP, regardless 
of diabetes status. Males, however, differed according to the presence or absence of diabetes. For men 
without diabetes the association between waist circumference and BMI with hs-CRP was much 
stronger than for men with diabetes. Namely, for the same waist circumference or BMI, men without 
diabetes had higher hs-CRP levels than men with diabetes. Still, no such relation was found in the 
literature or in our study for females, despite previous reports to the contrary [26,36].  
In general, body fatness had a greater affect on hs-CRP for subjects without diabetes than subjects 
with diabetes, which was an unexpected result. This finding may be partially explained by the 
influence of medications for diabetes. Since the analysis was layered by diabetes status, the potential 
confounding of medications taken only by subjects with diabetes could not be controlled for. Insulin, 
for example, has been shown to act as an anti-inflammatory modulator and some oral hypoglycemic 
agents (OHAs) can affect hs-CRP levels [37,38]. Thus, the use of insulin or OHAs could have 
artificially lowered hs-CRP levels in subjects with diabetes, making a difference between the groups 
difficult to detect.  Int. J. Environ. Res. Public Health 2010, 7          
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The single time point design of this study is a limitation of our research. Specifically, the temporal 
relationship between body fatness, T2D, inflammation or cardiovascular risk cannot be revealed. 
Furthermore, some bias may be introduced through the use of a semi-convenience sample. Hence, our 
findings cannot be generalized to the greater Cuban-American community. Another limitation to this 
study was the ratio of males to females, in that the study population included almost two females for 
every male. However, the value of the current research was augmented by the inclusion of both males 
and females, and by the resulting gender difference observed in this previously understudied 
population. Overall, our study has important clinical and public health implications. Cuban-Americans 
are the fastest growing Hispanic group at high-risk for both T2D and cardiovascular disease. Yet, little 
research has been conducted on Cuban-Americans separate from a general Hispanic population. This 
exploratory study highlights a possible role for gender and an influence of ethnicity. As the basis for 
future research, these findings may contribute to the development of ethnicity-based health 
interventions for chronic diseases.   
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